Table of Contents
and restated in connection with our Class D preferred stock financing in September 2015 and (iv) further amended effective as of October 2015. The third
amended and restated investor rights agreement, as amended, contains voting rights, information rights, rights of co-sale, pro rata participation rights and registration rights, among other things,
with certain holders of our capital stock. In addition, as described in "Management Board Composition and Election of Directors Board Composition," the third
amended and restated investor rights agreement, as amended, entitles certain holders of our capital stock to designate directors to our board. Pursuant to the terms of the agreement, each of these
rights, with the exception of the registrations rights, will terminate upon the closing of this offering, except for the registration rights as more fully described below in "Description of Capital
Stock Registration Rights."
REGENXBIO Exclusive License Agreement
In March 2014, we entered into an exclusive license agreement with ReGenX Biosciences, LLC, or ReGenX, predecessor to REGENXBIO
Inc, as described more fully in "Business Our Collaboration and License Agreements Strategic Collaborators and Relationships REGENXBIO."
Deerfield and Venrock, each a beneficial owner of more than 5% of our capital stock, are also beneficial owners of more than 5% of the capital stock of REGENXBIO, as of September 1, 2015. Our
payments to ReGenX totaled $2 million in 2014 and total $2.3 million as of September 30, 2015.
We have entered into employment-related agreements with our current and former executive officers, including Mr. Carbona. For
more information regarding these agreements, see "Executive Compensation Employment Agreements" and "Executive Compensation Potential Payments Upon
Termination or Change in Control."
Employment of Dr. Allan Kaspar
Since July 2013, Sixeva, and beginning in January 2014, we have employed Dr. Allan Kaspar, the brother of Dr. Brian
Kaspar. Dr. Allan Kaspar is currently our VP, Research and Development. In 2013, his compensation was $67,574. In 2014, his compensation was $181,692. In addition, in 2014, we granted
Dr. Allan Kaspar a stock option to purchase 82,800 shares of common stock, with a grant date fair value of $89,770.
We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other
things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law,
including indemnification of expenses such as attorneys' fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action
or proceeding by or in right of us, arising out of the person's services as a director or executive officer.
Stock Option Grants to Executive Officers and Directors
We have granted stock options to our named executive officer as more fully described in the section entitled "Executive Compensation."